» Articles » PMID: 38165731

Respiratory Control Minimizes Diaphragmatic Contraction and Dry Cough During Pulsed-field Ablation of Atrial Fibrillation

Abstract

Aims: Pulsed-field ablation (PFA) is a promising new ablation modality to treat atrial fibrillation. However, PFA can cause varying degrees of diaphragmatic contraction and dry cough, especially under conscious sedation. This prospective study presents a method to minimize the impact of PFA on diaphragmatic contraction and dry cough during the procedure.

Methods And Results: Twenty-eight patients underwent PFA for pulmonary vein (PV) and superior vena cava isolation under conscious sedation. Each patient received two groups of ablations in each vein: the control group allowed PFA application during any phase of respiratory cycle, while the test group used respiratory control, delivering PFA energy only at the end of expiration. A rating score system was developed to assess diaphragmatic contraction and dry cough. A total of 1401 control ablations and 4317 test ablations were performed. The test group had significantly lower scores for diaphragmatic contraction (P < 0.01) and dry cough (P < 0.001) in all PVs compared to the control group. The average relative reductions in scores for all PVs were 33-47% for diaphragmatic contraction and 67-83% for dry cough. The percentage of ablations with scores ≧2 for diaphragmatic contraction decreased significantly from 18.5-28.0% in the control group to 0.4-2.6% in the test group (P < 0.001). For dry cough, the percentage decreased from 11.9-43.7% in the control group to 0.7-2.1% in the test group.

Conclusion: Pulsed-field ablation application at the end of expiration can reduce the severity of diaphragmatic contraction and eliminate moderate and severe dry cough during PV isolation performed under conscious sedation.

Citing Articles

State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective.

Chun K, Miklavcic D, Vlachos K, Bordignon S, Scherr D, Jais P Europace. 2024; 26(6).

PMID: 38848447 PMC: 11160504. DOI: 10.1093/europace/euae134.

References
1.
Chen S, Schmidt B, Bordignon S, Tohoku S, Urbanek L, Chun J . Pulsed field ablation as first-line treatment to reduce atrial fibrillation burden documented by pacemaker. Pacing Clin Electrophysiol. 2022; 46(5):414-418. DOI: 10.1111/pace.14629. View

2.
Garcia R, Waldmann V, Vanduynhoven P, Nesti M, de Oliveira Figueiredo M, Narayanan K . Worldwide sedation strategies for atrial fibrillation ablation: current status and evolution over the last decade. Europace. 2021; 23(12):2039-2045. DOI: 10.1093/europace/euab154. View

3.
Ekanem E, Reddy V, Schmidt B, Reichlin T, Neven K, Metzner A . Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. 2022; 24(8):1256-1266. PMC: 9435639. DOI: 10.1093/europace/euac050. View

4.
Schoenbach K . From the basic science of biological effects of ultrashort electrical pulses to medical therapies. Bioelectromagnetics. 2018; 39(4):257-276. DOI: 10.1002/bem.22117. View

5.
Iacopino S, Colella J, Dini D, Mantovani L, Sorrenti P, Malacrida M . Sedation strategies for pulsed-field ablation of atrial fibrillation: focus on deep sedation with intravenous ketamine in spontaneous respiration. Europace. 2023; 25(9). PMC: 10434732. DOI: 10.1093/europace/euad230. View